Validation of the rosette inhibition test for the detection of early pregnancy in women.
The authors validated use of the rosette inhibition test for the detection of early pregnancy factor (EPF) in human pregnancy, first by optimizing conditions for the assay, using known pregnant and nonpregnant sera, and second, by examining the performance of this assay in three clinical situations: a "blind" study involving coded first-trimester sera showed 80% correlation with pregnancy status; serial assay of EPF activity in sera collected from normal women attempting to conceive, correlated with human chorionic gonadotropin beta-subunit (beta-hCG) levels and pregnancy status; a longitudinal study of serial serum samples through two normal pregnancies showing the continued presence of EPF until the early third trimester in each case. It was concluded that with the rosette inhibition assay, consistent demonstration of a pregnancy-associated substance (EPF) could be obtained.
D018835:Chaperonin 10; D006063:Chorionic Gonadotropin / Q000097:blood; D018997:Chorionic Gonadotropin, beta Subunit, Human; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000097:blood*; D008137:Longitudinal Studies; D008214:Lymphocytes / Q000276:immunology; D008598:Menstruation; D010446:Peptide Fragments / Q000097:blood; D010455:Peptides; D011247:Pregnancy; D011257:Pregnancy Proteins; D011259:Pregnancy Tests, Immunologic / Q000379:methods*; D012397:Rosette Formation; D013491:Suppressor Factors, Immunologic
D018835:Chaperonin 10; D006063:Chorionic Gonadotropin; D018997:Chorionic Gonadotropin, beta Subunit, Human; D007166:Immunosuppressive Agents; D010446:Peptide Fragments; D010455:Peptides; D011257:Pregnancy Proteins; D013491:Suppressor Factors, Immunologic; C025124:early pregnancy factor